Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS

Stevens, Kate I. ; Frangou, Eleni ; Shin, Jae Il ; Anders, Hans Joachim ; Bruchfeld, Annette ; Schönermarck, Ulf ; Hauser, Thomas ; Westman, Kerstin LU ; Fernandez-Juarez, Gema M. and Floege, Jürgen , et al. (2022) In Nephrology Dialysis Transplantation 37(8). p.1400-1410
Abstract

Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with... (More)

Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
IgA nephropathy, immunology, immunosuppression, rituximab, vasculitis
in
Nephrology Dialysis Transplantation
volume
37
issue
8
pages
11 pages
publisher
Oxford University Press
external identifiers
  • scopus:85131505857
  • pmid:35244174
ISSN
0931-0509
DOI
10.1093/ndt/gfac052
language
English
LU publication?
yes
id
bf90cab6-5f83-4d12-8573-4873f07f9417
date added to LUP
2022-12-29 11:17:21
date last changed
2025-01-11 20:07:38
@article{bf90cab6-5f83-4d12-8573-4873f07f9417,
  abstract     = {{<p>Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.</p>}},
  author       = {{Stevens, Kate I. and Frangou, Eleni and Shin, Jae Il and Anders, Hans Joachim and Bruchfeld, Annette and Schönermarck, Ulf and Hauser, Thomas and Westman, Kerstin and Fernandez-Juarez, Gema M. and Floege, Jürgen and Goumenos, Dimitrios and Turkmen, Kultigin and van Kooten, Cees and McAdoo, Stephen P. and Tesar, Vladimir and Segelmark, Mårten and Geetha, Duvuru and Jayne, David R.W. and Kronbichler, Andreas}},
  issn         = {{0931-0509}},
  keywords     = {{IgA nephropathy; immunology; immunosuppression; rituximab; vasculitis}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1400--1410}},
  publisher    = {{Oxford University Press}},
  series       = {{Nephrology Dialysis Transplantation}},
  title        = {{Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS}},
  url          = {{http://dx.doi.org/10.1093/ndt/gfac052}},
  doi          = {{10.1093/ndt/gfac052}},
  volume       = {{37}},
  year         = {{2022}},
}